ERBB2 and gastric cancer: Altogether, oxaliplatin administered at 5 μM had a certain killing effect on MKN45 cells, and could promote the conversion of M1 phenotype, demonstrating the potential that oxaliplatin synergistically enhanced the anti-tumoral efficacy of HF-CAR-PMs against HER2-positive GC.